Literature DB >> 9005992

EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.

K Tanaka1, T Iwakuma, K Harimaya, H Sato, Y Iwamoto.   

Abstract

The translocation t(11;22) is a common chromosomal abnormality detected both in Ewing's sarcoma and in primitive neuroectodermal tumor cells. The translocation results in an EWS-Fli1 fusion gene, made up of the 5' half of the EWS gene on chromosome 22 fused to the 3' half of the Fli1 gene on chromosome 11. Recent studies have evaluated possible roles of the fusion gene products. However, the biological significance of EWS-Fli1 is still unknown. Using a competitive polymerase chain reaction technique, we show here that there might be a correlation between the expression levels of the EWS-Fli1 fusion gene and the proliferative activities of Ewing's sarcoma and primitive neuroectodermal tumor cells. When the EWS-Fli1 expression is inhibited by antisense oligodeoxynucleotides against the fusion RNA, the growth of the tumor cells is significantly reduced both in vitro and in vivo. The data further indicate the growth inhibition of the cells by the antisense sequence might be mediated by G0/G1 block in the cell cycle progression. These results suggest that EWS-Fli1 may play an important role in the proliferation of the tumor cells, and the EWS-Fli1 fusion RNA could be used as a target to inhibit the growth of Ewing's sarcoma and primitive neuroectodermal tumor with the specific antisense oligonucleotide.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9005992      PMCID: PMC507791          DOI: 10.1172/JCI119152

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Competitive PCR.

Authors:  P D Siebert; J W Larrick
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

2.  Dynamic model of differentiation in Ewing's sarcoma cells. Comparative analysis of morphologic, immunocytochemical, and oncogene expression parameters.

Authors:  R Noguera; T J Triche; S Navarro; M Tsokos; A Llombart-Bosch
Journal:  Lab Invest       Date:  1992-02       Impact factor: 5.662

3.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.

Authors:  O Delattre; J Zucman; B Plougastel; C Desmaze; T Melot; M Peter; H Kovar; I Joubert; P de Jong; G Rouleau
Journal:  Nature       Date:  1992-09-10       Impact factor: 49.962

Review 4.  Nuclear proto-oncogenes fos and jun.

Authors:  L J Ransone; I M Verma
Journal:  Annu Rev Cell Biol       Date:  1990

Review 5.  Primary response genes induced by growth factors and tumor promoters.

Authors:  H R Herschman
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

6.  EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro.

Authors:  H Kovar; D N Aryee; G Jug; C Henöckl; M Schemper; O Delattre; G Thomas; H Gadner
Journal:  Cell Growth Differ       Date:  1996-04

7.  Myc and Max proteins possess distinct transcriptional activities.

Authors:  L Kretzner; E M Blackwood; R N Eisenman
Journal:  Nature       Date:  1992-10-01       Impact factor: 49.962

8.  Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression.

Authors:  S J Langer; D M Bortner; M F Roussel; C J Sherr; M C Ostrowski
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

9.  Quantitation of mRNA by the polymerase chain reaction.

Authors:  A M Wang; M V Doyle; D F Mark
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  The contribution of increased collagen synthesis to human glomerulosclerosis: a quantitative analysis of alpha 2IV collagen mRNA expression by competitive polymerase chain reaction.

Authors:  E P Peten; L J Striker; M A Carome; S J Elliott; C W Yang; G E Striker
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  75 in total

1.  EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

Authors:  Alexandre Prieur; Franck Tirode; Pinchas Cohen; Olivier Delattre
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

2.  Primitive neuroectodermal tumor of ovary in a young lady, confirmed with molecular and cytogenetic results--a rare case report with a diagnostic and therapeutic challenge.

Authors:  Vikas Ostwal; Bharat Rekhi; Vanita Noronha; Ranjan Basak; Sangeeta B Desai; Amita Maheshwari; Kumar Prabhash
Journal:  Pathol Oncol Res       Date:  2012-02-05       Impact factor: 3.201

Review 3.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

4.  EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.

Authors:  Tyler P Robin; Anna Smith; Erin McKinsey; Lisa Reaves; Paul Jedlicka; Heide L Ford
Journal:  Mol Cancer Res       Date:  2012-06-20       Impact factor: 5.852

5.  Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

Authors:  E de Alava; A Panizo; C R Antonescu; A G Huvos; F J Pardo-Mindán; F G Barr; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 6.  Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies.

Authors:  Mandeep S Tamber; Krishan Bansal; Muh-Lii Liang; Todd G Mainprize; Bodour Salhia; Paul Northcott; Michael Taylor; James T Rutka
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

7.  Anti-Epileptic Drug Targets Ewing Sarcoma.

Authors:  Shubhalaxmi Kayarthodi; Yasuo Fujimura; Jinbo Fang; Sharif Morsalin; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2014-06-01

Review 8.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

Review 9.  Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.

Authors:  Valerie B Sampson; Davida F Kamara; E Anders Kolb
Journal:  Expert Opin Drug Discov       Date:  2013-07-12       Impact factor: 6.098

10.  GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein.

Authors:  Elspeth Beauchamp; Gulay Bulut; Ogan Abaan; Kevin Chen; Akil Merchant; William Matsui; Yoshimi Endo; Jeffrey S Rubin; Jeffrey Toretsky; Aykut Uren
Journal:  J Biol Chem       Date:  2009-02-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.